Lubgen Farma Sp. zo.o., a wholly owned subsidiary of S.R. Burzynski (OTCBB:BZYR), has announced that the Polish government’s chief pharmaceutical inspector in Warsaw, Poland, approved plans for a manufacturing facility which will manufacture the company’s patented cancer therapy, Antineoplastons.
